This investigation finds that sarcopenia and metabolic metrics from PET imaging significantly affect survival in metastatic NSCLC, highlighting poor prognosis implications.
Key Points
Patients with sarcopenia had a median overall survival of 4.7 months, significantly lower than 9.8 months for non-sarcopenic patients.
Among the cohort, 74.2% were diagnosed with sarcopenia, correlating with reduced overall survival metrics.
Metabolic metrics from 18F-FDG PET imaging, such as SUVmax_T, MTV_T, and TLG_T, serve as independent predictors of overall survival in nsNSCLC.
The findings suggest that sarcopenia and detrimental metabolic metrics from PET imaging are linked to poorer survival outcomes in metastatic nsNSCLC patients.